Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Quadrivalent Recombinant Influenza Vaccine

Preclinical

1

Indications

1

Total Trials

0

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Influenza ImmunizationCompleted

Influenza ImmunizationPreclinical

Completed

Clinical

Trials by Indication[1]

Influenza Immunization1 trial

A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above

Completed· Sanofi logo

Sanofi·Preclinical·NCT06361875·908 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Quadrivalent Recombinant Influenza Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Quadrivalent Recombinant Influenza Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Sanofi

Related News